Xeris Biopharma Holdings, Inc. (XERS) key performance indicators and operating metrics (13 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Recorlev Net Revenue | 49.77M | FY2026-Q1 |
| Gvoke Net Revenue | 20.8M | FY2026-Q1 |
| Keveyis Net Revenue | 11.89M | FY2026-Q1 |
| Total Product Revenue | 82.45M | FY2026-Q1 |
| Royalty, Contract and Other Revenue | 673K | FY2026-Q1 |
| Gvoke Product Revenue | 24.65M | FY2025-Q4 |
| Keveyis Product Revenue | 12.8M | FY2025-Q4 |
| Recorlev Product Revenue | 45.33M | FY2025-Q4 |
| Product Revenue, Net | 83.43M | FY2025-Q4 |
| Adjusted Earnings Before Interest, Taxes, Depreciation and Amortization | 25.1M | FY2025-Q4 |
| Other Product Revenue | 652K | FY2025-Q4 |
| Adjusted EBITDA | 12.5M | FY2025-Q2 |
| Average Number of Patients on Recorlev (Year-Over-Year Increase) | 122.00 percent | FY2025-Q2 |
Back to XERS overview · XERS earnings · XERS holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.